RxSight at Stifel Forum: Navigating Market Challenges

During the Stifel 2025 Virtual Ophthalmology Forum, RxSight (RXST) expressed optimism for growth in the latter half of 2025, contingent on economic stabilization, despite macroeconomic headwinds and competitive pressures, notably from Alcon's PanOptix Pro. RxSight reported an increase in market share from approximately 10% in Q4 to 11-12% in Q1 and highlighted new utilization programs aimed at enhancing performance across varying adoption levels. The company anticipates year-over-year growth in LDD sales compared to 2024, with the Light Adjustable Lens (LAL) remaining a key driver in the premium IOL market.

Analysis

RxSight, Inc. (NASDAQ:RXST) detailed its strategic positioning and outlook at the Stifel 2025 Virtual Ophthalmology Forum, expressing optimism for renewed growth in the second half of 2025, contingent upon macroeconomic and political stabilization. The company reported an increase in its Light Adjustable Lens (LAL) market share from approximately 10% in Q4 2024 to an estimated 11-12% in Q1 2025, despite broader premium intraocular lens (IOL) market headwinds attributed to equity market volatility impacting cataract surgery volumes. RxSight acknowledged that these macroeconomic factors affected early Q2 performance but anticipates stabilization, noting improved LAL procedural volumes in late April coinciding with less macro noise. Management highlighted that the LAL system remains the primary growth driver in the premium IOL market, with a significant portion of LAL patients (40-45%) migrating from monofocal IOLs. Competitive pressures, notably from Alcon’s PanOptix Pro, persist; however, RxSight believes current competitive incentivization programs are transient and unsustainable, and that its LAL technology offers distinct clinical advantages not easily replicated by competitors' incremental product updates. The company reported strong Light Delivery Device (LDD) sales in Q1, with expectations of year-over-year growth compared to 2024, supported by a stable sales funnel and a six-month LDD payback period for physicians. To further drive growth, RxSight is implementing new utilization programs focused on transferring best practices from high-performing sites to others, aiming to enhance clinical skills and marketing techniques. A challenge noted was the 2024 cohort of surgeons showing slower adaptation rates compared to previous years, potentially impacting installation growth, though the company expects this to align with broader market trends. Overall, RxSight's guidance for H2 2025 hinges on moderating macroeconomic impacts and an abatement of intense competitive trialing activities.

Key Decisions for Investors

• Investors should monitor macroeconomic indicators, particularly equity market performance and consumer sentiment, as RxSight's H2 2025 growth outlook is heavily dependent on economic stabilization.
• Closely track RxSight's market share progression and LAL volume growth, especially in the context of competitive product launches like Alcon's PanOptix Pro, to assess the LAL's sustained market penetration.
• Evaluate the effectiveness of new utilization programs and the adaptation trends of recent surgeon cohorts, as these are key internal levers for driving same-store sales and overall LAL adoption.
• Consider the company's ability to achieve the higher end of its 2025 sales guidance, which relies on the anticipated moderation of competitive pressures and a more stable economic environment in the latter half of the year.